FMP
EQRx, Inc.
EQRXW
NASDAQ
Inactive Equity
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. Its product pipeline in development includes Aumolertinib, an EGFR inhibitor for the treatment of ?EGFR-mutated? non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for the treatment of ?stage III and IV ?NSCLC; Lerociclib, a CDK4/6 inhibitor to treat HR+/HER2- breast cancer; and EQ176, an anti-PD-1?antibody for the treatment of liver cancer. The company has partnerships with Exscientia and AbCellera Biologics Inc. EQRx, Inc. was founded in 2020 and is based in Cambridge, Massachusetts.
0.0455 USD
0 (0%)
Earnings
Dividends
We are unable to load the chart at this time.
Splits
We are unable to load the chart at this time.
From:
To:
Date
Revenue
Earnings
Estimated Earnings
Surprise
2023-09-30
0
-0
0
-
2023-06-30
0
-0
0
-
2023-03-31
0
-0
0
-
2022-12-31
0
0
0
-
